Two tier 1 customers renew contracts announces Osirium Technologies

Ikaba Koyi Sharecast | 12 Oct, 2017 13:02 | | |

contract-945619_1920

Osirium Technologies

159.00

17:20 20/10/17
-0.00%
-0.00
  • 2,268.66
  • 0.07%1.48
  • Max: 2,271.01
  • Min: 2,264.33
  • Volume: 0
  • MM 200 : n/a
08:55 23/10/17
  • 1,021.20
  • 0.09%0.87
  • Max: 1,022.54
  • Min: 1,019.90
  • Volume: 0
  • MM 200 : n/a
09:00 23/10/17

Two tier 1 customers, a telecommunications group and global aerospace and defence company, have decided to renew their contracts, announced Osirium Technologies on Thursday.

According to the UK headquartered cyber-security SaaS provider, the companies had opted to renew their contracts for 12 months and 24 months, respectively.

Management added that under the terms of these contracts it would be able to deliver its full product offering comprising of Privileged Account Management, Privileged Task Management and Privileged Session Management modules as well as associated consultancy services.

David Guyatt, chief executive officer, saw the decision by the two global businesses to renew their contracts as providing further validation of its PxM technology and its ability to provide cyber-security protection.

"We are delighted that these two global businesses across two different vertical sectors continue to value our partnership by renewing their contracts. This provides further validation of our simple to use and easy to deploy PxM technology and its ability to be installed quickly and scale across international businesses to assist them in cyber-security protection."

More news

08:24 Capita's sale of Asset Services arm nears completion

Capita expects to complete the sale of its Asset Services businesses to Link Administration a week on Friday.

08:21 Pendragon warns on profit amid weaker new car demand

Car dealership Pendragon warned on Monday that full-year profit will be hit by weaker new car demand and pricing on used cars, as it announced that chairman Mel Egglenton has stepped down with immediate effect.

08:03 Electra Private Equity eyes new flexible approach, declares another dividend

After completing a strategic review and reverted to internal management of its investments, Electra Private Equity has decided "current market conditions do not support new investment" and so proposed handing back most of its cash and dropping its focus on private equity to become "more flexible".

08:02 CRH gets shareholder approval for Ash Grove deal

Building materials company CRH is set to push ahead with its $3.5bn acquisition of US cement manufacturer Ash Grove Cement after receiving shareholder approval for the deal.

07:51 AstraZeneca diabetes drug gets FDA approval

AstraZeneca said that the US Food and Drug Administration has approved a new formulation of its type-2 diabetes treatment Bydureon.

07:41 GlaxoSmithKline's Shingrix gets US FDA approval

GlaxoSmithKline said on Monday that the US Food and Drug Administration has approved Shingrix for the prevention of shingles in adults over 50.

07:38 Renewi sees full-year results 'significantly above' previous expectations

Waste-to-product business Renewi said on Monday that results for the year are expected to be “significantly above” its previous expectations following a particularly strong performance in September.

07:33 London pre-open: Stocks to nudge lower as pound gains ground

London stocks were set to nudge a touch lower at the open on Monday as the pound gains ground against the dollar and the euro.

07:31 Spire rejects rival's advances, Renewi raises expectations

London open The FTSE 100 is expected to gain roughly six points on Monday, according to traders in the City, having closed the prior week at 7,523.23.

07:20 Spire Healthcare rebuffs offer from Mediclinic

Spire Healthcare has rejected a cash-and-shares offer from fellow private hospital operator Mediclinic International.